BIOSPECIFICS TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2010-12-08: Form 8-K; Period of report 2010-12-08; Description 8.01 Other Events; Details 8.01.
- 2010-11-22: Form 8-K; Period of report 2010-11-22; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2010-11-08: Form 8-K; Period of report 2010-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2010-11-05: Form 8-K; Period of report 2010-11-05; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2010-12-08 | 8-K | 2010-12-08 | 8.01 Other Events | 8.01 On December 7, 2010, the Company announced that The Journal of Hand Surgery has published in its December 2010 online edition pivotal CORD II phase III clinical trial of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class biologic, conducted by the Company’s strategic partner Auxilium Pharmaceuticals Inc., for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord. | form8k.htm |
| 2010-11-22 | 8-K | 2010-11-22 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in November 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | d8k.htm |
| 2010-11-08 | 8-K | 2010-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2010, the Company announced its financial and operating results for the fiscal quarter ended September 30, 2010. | form8k.htm |
| 2010-11-05 | 8-K | 2010-11-05 | 8.01 Other Events | 8.01 On November 3, 2010, the Company announced that it has received $426,000 in grant funding under the Qualifying Therapeutic Discovery Project Program. | form8-k.htm |
| 2010-10-21 | 8-K | 2010-10-21 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on October 21, 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | d8k.htm |
| 2010-10-15 | 8-K | 2010-10-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 11, 2010, the Board of Directors of the Company (the “Board”) revised its compensation policy for independent directors. | form8k.htm |
| 2010-10-14 | 8-K | 2010-10-13 | 8.01 Other Events | 8.01 On October 12, 2010, the Company announced that its partner Auxilium Pharmaceuticals, Inc. has dosed the first subject in the global Phase 3 program of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of Peyronie's disease. | d8k.htm |
| 2010-09-13 | 8-K | 2010-09-13 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on September 13, 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | d8k.htm |
| 2010-08-06 | 8-K | 2010-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2010, the Company announced its financial and operating results for the fiscal quarter ended June 30, 2010. | d8k.htm |
| 2010-07-13 | 8-K | 2010-07-13 | 8.01 Other Events | 8.01 On July 12, 2010, the Company announced that its strategic partner Auxilium Pharmaceuticals, Inc. has provided an update on XIAFLEX®, its injectable collagenase product currently marketed in the U.S. for the treatment of Dupuytren’s contracture. | form8k.htm |
| 2010-06-21 | 8-K | 2010-06-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 17, 2010, the Board of Directors of the Company (the “Board”) determined that, absent special circumstances, no new options will be granted to directors, officers, employees or consultants. 5.07 The 2010 annual meeting of stockholders of the Company (the “2010 Annual Meeting”) was held on June 17, 2010. | form8k.htm |
| 2010-06-21 | 8-K | 2010-06-21 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on June 21, 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | d8k.htm |
| 2010-06-09 | 8-K | 2010-06-09 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on June 9, 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | d8k.htm |
| 2010-06-04 | 8-K | 2010-06-04 | 8.01 Other Events | 8.01 On June 4, 2010, the Company issued a press release announcing that its Board of Directors has authorized the repurchase of up to $2 million of its outstanding common stock. | form8k.htm |
| 2010-05-13 | 8-K | 2010-05-13 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on May 13, 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | d8k.htm |
| 2010-05-07 | 8-K | 2010-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2010, the Company announced its financial and operating results for the fiscal quarter ended March 31, 2010. | form8k.htm |
| 2010-03-26 | 8-K | 2010-03-26 | 8.01 Other Events | 8.01 On March 25, 2010, the Company announced that the Company’s Board of Directors has scheduled its Annual Meeting of Stockholders (“Meeting”) to be held on Thursday, June 17, 2010. | form8k.htm |
| 2010-03-11 | 8-K | 2010-03-11 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on March 11, 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2010-03-10 | 8-K | 2010-03-10 | 2.02 Results of Operations and Financial Condition | 2.02 On March 10, 2010, the Company announced its financial and operating results for the fiscal quarter and full year ended December 31, 2009. | form8k.htm |
| 2010-03-05 | 8-K | 2010-03-05 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in March 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2010-02-08 | 8-K | 2010-02-08 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on February 8, 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2010-02-03 | 8-K | 2010-02-03 | 8.01 Other Events | 8.01 On February 2, 2010, the Company announced that the U.S. Food and Drug Administration has approved XIAFLEX™ for the treatment of adult Dupuytren’s contracture patients with a palpable cord. | form8k.htm |
| 2010-02-02 | 8-K | 2010-02-02 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in February 2010 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2010-01-21 | 8-K | 2010-01-21 | 8.01 Other Events | 8.01 On January 21, 2010, the Company announced the commencement of European regulatory review of XIAFLEX™ for the treatment of Dupuytren’s disease. | form8k.htm |
| 2010-01-08 | 8-K | 2010-01-08 | 7.01 Regulation FD Disclosure | 7.01 Commencing January 11, 2010, our President, Thomas L. Wegman, will present to various investors using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | bstc010810f8k.htm |